Literature DB >> 21135183

Alkylated porphyrins have broad antiviral activity against hepadnaviruses, flaviviruses, filoviruses, and arenaviruses.

Haitao Guo1, Xiaoben Pan, Richeng Mao, Xianchao Zhang, Lijuan Wang, Xuanyong Lu, Jinhong Chang, Ju-Tao Guo, Shendra Passic, Fred C Krebs, Brian Wigdahl, Travis K Warren, Cary J Retterer, Sina Bavari, Xiaodong Xu, Andrea Cuconati, Timothy M Block.   

Abstract

We screened ∼2,200 compounds known to be safe in people for the ability to reduce the amount of virion-associated hepatitis B virus (HBV) DNA in the culture medium of producer cells. These efforts led to the discovery of an alkylated porphyrin, chlorophyllide, as the compound that achieved the greatest reduction in signal. Here we report that chlorophyllide directly and quantitatively disrupted HBV virions at micromolar concentrations, resulting in the loss of all detectable virion DNA, without detectably affecting cell viability or intracellular viral gene products. Chemophores of chlorophyllide were also tested. Chlorin e6, a metal-free chlorophyllide-like molecule, showed the strongest antiviral activity against HBV as well as profound antiviral effects on other enveloped viruses, such as hepatitis C virus (HCV), human immunodeficiency virus (HIV), dengue virus (DENV), Marburg virus (MARV), Tacaribe virus (TCRV), and Junin viruses (JUNV). Remarkably, chlorin e6 inactivated DENV at subnanomolar-level concentrations. However, the compound had no antiviral effect against encephalomyocarditis virus and adenovirus, suggesting that chlorin e6 may be less active or inactive against nonenveloped viruses. Although other porphyrin derivatives have been previously reported to possess antiviral activity, this is the first analysis of the biochemical impact of chlorophyllide and chlorin e6 against HBV and of the dramatic anti-infectivity impact upon DENV. The possible application of this family of compounds as antiviral agents, as microbicides and systemic virus neutralizing agents, is discussed.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21135183      PMCID: PMC3028764          DOI: 10.1128/AAC.00989-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  32 in total

1.  Specific inhibition of HIV-1 protease by boronated porphyrins.

Authors:  D L DeCamp; L M Babé; R Salto; J L Lucich; M S Koo; S B Kahl; C S Craik
Journal:  J Med Chem       Date:  1992-09-04       Impact factor: 7.446

Review 2.  Hepatitis B virus biology.

Authors:  C Seeger; W S Mason
Journal:  Microbiol Mol Biol Rev       Date:  2000-03       Impact factor: 11.056

Review 3.  Immunopathological mechanisms in dengue and dengue hemorrhagic fever.

Authors:  Sharone Green; Alan Rothman
Journal:  Curr Opin Infect Dis       Date:  2006-10       Impact factor: 4.915

4.  Native hepatitis B virions and capsids visualized by electron cryomicroscopy.

Authors:  Kelly A Dryden; Stefan F Wieland; Christina Whitten-Bauer; John L Gerin; Francis V Chisari; Mark Yeager
Journal:  Mol Cell       Date:  2006-06-23       Impact factor: 17.970

5.  The insertion domain of the duck hepatitis B virus core protein plays a role in nucleocapsid assembly.

Authors:  Haitao Guo; Carol E Aldrich; Jeffry Saputelli; Chunxiao Xu; William S Mason
Journal:  Virology       Date:  2006-07-11       Impact factor: 3.616

6.  Hepatitis B virus particle formation in the absence of pregenomic RNA and reverse transcriptase.

Authors:  Wiebke Schormann; Anke Kraft; Dirk Ponsel; Volker Bruss
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

7.  Cryo-electron microscopy of hepatitis B virions reveals variability in envelope capsid interactions.

Authors:  Stefan Seitz; Stephan Urban; Christoph Antoni; Bettina Böttcher
Journal:  EMBO J       Date:  2007-08-30       Impact factor: 11.598

8.  A virocidal amphipathic {alpha}-helical peptide that inhibits hepatitis C virus infection in vitro.

Authors:  Guofeng Cheng; Ana Montero; Pablo Gastaminza; Christina Whitten-Bauer; Stefan F Wieland; Masanori Isogawa; Brenda Fredericksen; Suganya Selvarajah; Philippe A Gallay; M Reza Ghadiri; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

9.  Experimental grounds for using chlorin e6 in the photodynamic therapy of malignant tumors.

Authors:  G A Kostenich; I N Zhuravkin; E A Zhavrid
Journal:  J Photochem Photobiol B       Date:  1994-03       Impact factor: 6.252

10.  Hepatitis B virus infection is dependent on cholesterol in the viral envelope.

Authors:  Corinna M Bremer; Christiane Bung; Nicole Kott; Martin Hardt; Dieter Glebe
Journal:  Cell Microbiol       Date:  2008-11-05       Impact factor: 3.715

View more
  21 in total

1.  Mechanisms of Vesicular Stomatitis Virus Inactivation by Protoporphyrin IX, Zinc-Protoporphyrin IX, and Mesoporphyrin IX.

Authors:  Christine Cruz-Oliveira; Andreza F Almeida; João M Freire; Marjolly B Caruso; Maria A Morando; Vivian N S Ferreira; Iranaia Assunção-Miranda; Andre M O Gomes; Miguel A R B Castanho; Andrea T Da Poian
Journal:  Antimicrob Agents Chemother       Date:  2017-05-24       Impact factor: 5.191

2.  Detection of Hepatitis B Virus Particles Released from Cultured Cells by Particle Gel Assay.

Authors:  Ran Yan; Dawei Cai; Yuanjie Liu; Haitao Guo
Journal:  Methods Mol Biol       Date:  2017

3.  The Interferon-Inducible Protein Tetherin Inhibits Hepatitis B Virus Virion Secretion.

Authors:  Ran Yan; Xuesen Zhao; Dawei Cai; Yuanjie Liu; Timothy M Block; Ju-Tao Guo; Haitao Guo
Journal:  J Virol       Date:  2015-06-24       Impact factor: 5.103

4.  Screening and identification of compounds with antiviral activity against hepatitis B virus using a safe compound library and novel real-time immune-absorbance PCR-based high throughput system.

Authors:  Jason Lamontagne; Courtney Mills; Richeng Mao; Cally Goddard; Dawei Cai; Haitao Guo; Andy Cuconati; Timothy Block; Xuanyong Lu
Journal:  Antiviral Res       Date:  2013-02-13       Impact factor: 5.970

Review 5.  Progress in the experimental therapy of severe arenaviral infections.

Authors:  Brian B Gowen; Mike Bray
Journal:  Future Microbiol       Date:  2011-12       Impact factor: 3.165

6.  PD 404,182 is a virocidal small molecule that disrupts hepatitis C virus and human immunodeficiency virus.

Authors:  Ana Maria Chamoun; Karuppiah Chockalingam; Michael Bobardt; Rudo Simeon; Jinhong Chang; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

7.  Evaluation of PD 404,182 as an anti-HIV and anti-herpes simplex virus microbicide.

Authors:  Ana M Chamoun-Emanuelli; Michael Bobardt; Bernard Moncla; Marie K Mankowski; Roger G Ptak; Philippe Gallay; Zhilei Chen
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

8.  The cytoprotective enzyme heme oxygenase-1 suppresses Ebola virus replication.

Authors:  Lindsay Hill-Batorski; Peter Halfmann; Gabriele Neumann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2013-10-09       Impact factor: 5.103

9.  Heme and HO-1 Inhibition of HCV, HBV, and HIV.

Authors:  Warren N Schmidt; M Meleah Mathahs; Zhaowen Zhu
Journal:  Front Pharmacol       Date:  2012-10-04       Impact factor: 5.810

Review 10.  Potential vaccines and post-exposure treatments for filovirus infections.

Authors:  Brian M Friedrich; John C Trefry; Julia E Biggins; Lisa E Hensley; Anna N Honko; Darci R Smith; Gene G Olinger
Journal:  Viruses       Date:  2012-09-21       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.